Hematopoietic NeoplasmNCT07691008
Wearable Data for Personalized Prognostication in Cancer: A Registry Protocol
An observational study of Hematopoietic Neoplasm and Malignant Solid Neoplasm, run by City of Hope Medical Center.
Trial summary
This study receives physiological and lifestyle-related data from mobile phones to create an institutional database. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Hematopoietic Neoplasm, Malignant Solid Neoplasm, Lymphatic System Neoplasm
- What is being tested?
- Non-Interventional Study
- How many people
- 1,200 participants
- Where
- No sites listed yet
- Study dates
- 1 Dec 2026to 1 Dec 2034
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Patients and employees at City of Hope MedicalCenter that own an apple mobile device.
Who may be able to join
- Age: ≥ 18 years
- Has Apple Health app on personal device with valid iOS operating software (i.e., iOS 15.0 or higher)
- Has a registered MyChart/MyCityofHope account (or be willing to register for one) and the app downloaded onto the personal device that also contains the Apple Health app with their data
- Ability to read and understand English to review MyChart/MyCityofHope on-screen instructions to sync and share Apple Health data
- Meets one of the below criteria:
- Any patient at City of Hope who had and/or has a cancer-related visit (e.g., high risk, newly diagnosed, receiving treatment, active follow-up, survivorship etc.)
- City of Hope employee
Who cannot join
- Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)
- City of Hope employees listed on the study roster or who manage employees listed on the study roster
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
This study receives physiological and lifestyle-related data from mobile phones to create an institutional database.
Read the detailed description
This study will have two distinct stages. Stage 1 will examine and refine the utility and feasibility of the Apple Health-Epic platform in a small, convenience-driven patient cohort to ensure platform robustness and patient feasibility prior to initiating larger recruitment efforts in Stage 2. The objectives of Stage 2 will be to conduct enterprise-wide enrollment to build a large registry database permitting investigation of future specific questions that will be addressed in subsequent retrospective research protocols linked to this registry protocol.
- Conditions
- Hematopoietic Neoplasm, Malignant Solid Neoplasm, Lymphatic System Neoplasm, Hematopoietic and Lymphatic System Neoplasm
- Being tested
- Non-Interventional Study
- Medical subject headings
- Hematologic Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Non-Interventional StudyOther
Also called Non-Interventional Observational Study, non-interventional study, Noninterventional (Observational) Study
Non-Interventional Study
| Study group | Role | What they receive |
|---|---|---|
| Observational | Participants have health data collected from their mobile phone for up to 5 years throughout the study. Receives: Other: Non-Interventional Study |
What is being measured
The primary outcome is the main question the study is designed to answer.
Feasibility of data collection
The proportion of participants for whom a successful data connection is established between their Apple Health data and the study registry will be quantified". Then for each variable captured by Apple Health, we will quantify the following feasibility metrics for data collection, evaluated separately for the retrospective (up to 8 years) and prospective (up to 5 years) data periods:
For each subject, the total amount of retrospective (and prospective) HealthKit data available per patient in days and months will be calculated.
For each subject, the number of days per week that a variable is available will be estimated and summarized by the average and standard deviation across weeks (or months).
For both 1-2, the metrics will be calculated when pooling all available data, and separately for windows of 6 months. We will examine histograms and boxplots of the distributions across the cohort.
Measured: Up to 8.5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Jul 2026
- Study start1 Dec 2026 (estimated)
- Primary completion1 Dec 2028 (estimated)
- Study completion1 Dec 2034 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hematopoietic NeoplasmStudies of the same condition, open and under way.
- More trials run by City of Hope Medical CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 1,200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- City of Hope Medical Center
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Lee Jones, Principal investigator, City of Hope Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07691008
- Sponsor's protocol ID
- 260059
- Status last verified
- Jul 2026
- First submitted
- 1 Jun 2026
- Last updated
- 8 Jul 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 8 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Wearable Data for Personalized Prognostication in Cancer: A Registry Protocol
- ClinicalTrials.gov ID
- NCT07691008
- Acronym / sponsor ID
- 260059
- Conditions
- Hematopoietic Neoplasm, Malignant Solid Neoplasm, Lymphatic System Neoplasm, Hematopoietic and Lymphatic System Neoplasm
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 1,200 participants (estimated)
- Lead sponsor
- City of Hope Medical CenterUniversity, hospital or other
- Study start
- 1 Dec 2026 (estimated)
- Primary completion
- 1 Dec 2028 (estimated)
- Study completion
- 1 Dec 2034 (estimated)
- First posted
- 8 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study receives physiological and lifestyle-related data from mobile phones to create an institutional database.
Detailed description
This study will have two distinct stages. Stage 1 will examine and refine the utility and feasibility of the Apple Health-Epic platform in a small, convenience-driven patient cohort to ensure platform robustness and patient feasibility prior to initiating larger recruitment efforts in Stage 2. The objectives of Stage 2 will be to conduct enterprise-wide enrollment to build a large registry database permitting investigation of future specific questions that will be addressed in subsequent retrospective research protocols linked to this registry protocol.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Observational | – | Other: Non-Interventional StudyParticipants have health data collected from their mobile phone for up to 5 years throughout the study. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Patients and employees at City of Hope MedicalCenter that own an apple mobile device.
Key inclusion criteria (7 listed)
- Age: ≥ 18 years
- Has Apple Health app on personal device with valid iOS operating software (i.e., iOS 15.0 or higher)
- Has a registered MyChart/MyCityofHope account (or be willing to register for one) and the app downloaded onto the personal device that also contains the Apple Health app with their data
- Ability to read and understand English to review MyChart/MyCityofHope on-screen instructions to sync and share Apple Health data
- Meets one of the below criteria:
Key exclusion criteria (2 listed)
- Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)
- City of Hope employees listed on the study roster or who manage employees listed on the study roster
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Non-Interventional StudyAlso: Non-Interventional Observational Study, non-interventional study, Noninterventional (Observational) StudyNon-Interventional Study | Other | Observational |
Primary outcome
Feasibility of data collection
Time frame: Up to 8.5 years
The proportion of participants for whom a successful data connection is established between their Apple Health data and the study registry will be quantified". Then for each variable captured by Apple Health, we will quantify the following feasibility metrics for data collection, evaluated separately for the retrospective (up to 8 years) and prospective (up to 5 years) data periods: For each subject, the total amount of retrospective (and prospective) HealthKit data available per patient in days and months will be calculated. For each subject, the number of days per week that a variable is available will be estimated and summarized by the average and standard deviation across weeks (or months). For both 1-2, the metrics will be calculated when pooling all available data, and separately for windows of 6 months. We will examine histograms and boxplots of the distributions across the cohort.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Jul 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Hematopoietic Neoplasm
Active, not recruiting
The Effect of Exercise and Nicotinamide Riboside Muscle Health and Insulin Resistance in Survivors of Childhood Cancer
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
RecruitingPhase 1
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
Malignancy, Hematologic, Neoplasms, Hematologic
Active, not recruiting
Virtual Art Therapy Assisted Re-Integration to Improve Biopsychosocial Outcomes in Adolescent and Young Adult Cancer Survivors, AVATARS Trial
Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm
Active, not recruiting
A Collaborative Intervention for Improving Cancer Pain Management in Cancer Survivors
Hematopoietic and Lymphoid System Neoplasm, Malignant Solid Neoplasm
Active, not recruitingPhase 2
Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or Incurable Hematologic Malignancies
Anxiety, Depression
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Lee Jones principal investigator
City of Hope Medical Center
Questions about this trial
What is this clinical trial studying?
An observational study of Hematopoietic Neoplasm and Malignant Solid Neoplasm, run by City of Hope Medical Center.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 8 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Lee Jones (626-761-2214, leejones@coh.org), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Feasibility of data collection (time frame: Up to 8.5 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Jul 2026; AzTrials last refreshed its copy on 31 Oct 2026.